UK Gupta, anticounterfeiting industry veteran, founder, and former President of the Authentication Solution Providers Association (ASPA) and CMD, Holostik India passed away on June 1, 2021.
London-headquartered AMO Pharma has announced the launch of a ‘pivotal’ phase III study of its congenital myotonic dystrophy (CDM1) candidate AMO-02 (tideglusib).
Suboptimal diet accounts for 18.2 percent of all cardiometabolic disease (CMD) costs in the United States, according to a study published online December in PLOS Medicine.
Collaborative Medicinal Development, LLC) ("CMD"), a clinical stage biopharmaceutical company with a portfolio of candidates for treatment of neurological and neuropsychiatric diseases.